

## FORM 7

### MONTHLY PROGRESS REPORT

Name of CNSX Issuer: **Entheon Biomedical Corp.** (“the “Issuer”).

Trading Symbol: **ENBI**

Number of Outstanding Listed Securities: **47,116,750**

Date: **December, 2020**

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**On December 1, the Issuer announced that it had entered into a Clinical Study Agreement with the Contract Research Organization (CRO) Centre for Human Drug Research (CHDR) to conduct an early phase human clinical trial with DMT.**

**On December 4, the Issuer announced a strategic investment in Wonder Scientific Inc. (“Wonder Scientific”). Wonder Scientific’s team of University Researchers and Product Development experts create custom, naturally derived, active pharmaceutical ingredients (APIs) to supply the growing global clinical and commercial demand for psychedelics.**

**In addition, the Issuer announced that it had entered into an investor relations consulting agreement with Mr. Joseph Cullen.**

**On December 9, the Issuer announced it had entered into a drug-supply agreement (the “Agreement”) with Psygen Labs Inc. (“Psygen”). Under the terms of the Agreement, Psygen will supply the Issuer with non-GMP and GMP (good manufacturing practice) quality N,N-dimethyltryptamine drug substances (“DMT”) for upcoming formulation, preclinical, clinical, and post-approval commercialization phases under the European Medicines Agency (EMA) regulatory framework.**

**On December 18, the Issuer announced that it was proceeding with a non-brokered private placement financing of 4,266,997 Units at a price of CDN\$0.75 per Unit for gross proceeds of CDN\$3,200,247.75 (the “Placement”).**

**On December 24, the Issuer announced that it had closed the Placement for total gross proceeds of CAD \$3,174,374.25.**

2. Provide a general overview and discussion of the activities of management.

**Management has been focused on developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (“DMT Products”) for the purposes of treating addiction and substance use disorders.**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs

and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**This section is not applicable to the Issuer.**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**This section is not applicable to the Issuer.**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**As described in Section 1, the Issuer entered into new business relationships with the CRO for CHDR, Wonder Scientific, Psygen and Mr. Joseph Cullen. Wonder Scientific and Mr. Cullen are related parties, as Wonder Scientific and the Issuer share a common director and Mr. Cullen is performing investor relations activities. The relationships with the CRO for CHDR and Psygen are arm's-length.**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**This section is not applicable to the Issuer.**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**As described in Section 1, the Issuer acquired unsecured convertible debentures of Wonder Scientific for an aggregate price of \$50,000.**

8. Describe the acquisition of new customers or loss of customers.

**This section is not applicable to the Issuer.**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**This section is not applicable to the Issuer.**

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

**As described in Section 1, the Issuer engaged Mr. Cullen as a consultant to the Issuer to provide investor relations activities.**

11. Report on any labour disputes and resolutions of those disputes if applicable.

**This section is not applicable to the Issuer.**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the

proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**This section is not applicable to the Issuer.**

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**This section is not applicable to the Issuer.**

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds <sup>(1)</sup>
Units	4,232,499	(2)	\$3,174,374.25 to be used towards clinical trials and general working capital
Finder's Warrants	168,490	(3)	N/A
Stock Options	3,175,000	(4)	N/A
Common Shares	1,278,732	(5)	\$791,242.99 to be used towards clinical trials and general working capital

(1) State aggregate proceeds and intended allocation of proceeds.

(2) Pursuant to the Placement. Each unit consists of one common share and one-half of one warrant, each whole warrant exercisable into an additional common share at \$1.00 for a period of 2 years, subject to accelerated expiry.

(3) Pursuant to the Placement. Each finder's warrant is exercisable at \$0.75 into a unit consisting of one common share and one-half of one warrant, each whole warrant exercisable into an additional common share at \$1.00 for a period of 2 years, and is subject to accelerated expiry.

(4) The Issuer granted stock options to directors, officers and consultants of the Issuer, exercisable at \$0.71 for a period of 5 years.

(5) Pursuant to the exercise of warrants at prices between \$0.45 to \$0.78 per share.

15. Provide details of any loans to or by Related Persons.

**This section is not applicable to the Issuer.**

16. Provide details of any changes in directors, officers or committee members.

**On December 29, the Issuer established and adopted a Compensation and Nomination Committee and a Disclosure Committee. Ruth Chung, Christopher Gondi and Timothy Ko were appointed to the Compensation and Nomination Committee. Ruth Chun, Andre Hegle and Timothy Ko were appointed to the Disclosure Committee.**

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

**This section is not applicable to the Issuer.**

### Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: January 6, 2021

Brandon Schwabe  
Name of Director or Senior Officer

"Brandon Schwabe"  
Signature

CFO  
Official Capacity

<b>Issuer Details</b> Name of Issuer Entheon Biomedical Corp.	For Month End December	Date of Report YY/MM/D 21/01/06
Issuer Address 211-3030 Lincoln Avenue		
City/Province/Postal Code Coquitlam, BC, V3B 6B4	Issuer Fax No. n/a	Issuer Telephone No. (604) 562-3932
Contact Name Timothy Ko	Contact Position CEO	Contact Telephone No. (604) 562-3932
Contact Email Address: timothy@entheonbiomedical.com	Web Site Address <a href="https://entheonbiomedical.com">https://entheonbiomedical.com</a>	